Want to see IMNM full AI Analyst Report?
IMNM Stock Chart & Stats
$29.38
$0.20(0.91%)
At close: 4:00 PM EDT
$29.38
$0.20(0.91%)
Day’s Range― - ―
52-Week Range$8.67 - $30.06
Previous CloseN/A
Volume615.24K
Average Volume (3M)1.56M
Market Cap
$3.13B
Enterprise Value$1.88K
Total Cash (Recent Filing)$520.00M
Total Debt (Recent Filing)$4.59M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 16, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding113,577,630
10 Day Avg. Volume1,063,226
30 Day Avg. Volume1,564,409
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.30Price Target Upside23.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.29
Revenue Forecast (FY)$333.33K
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces interest and refinancing pressure, while the substantial equity base provides a balance-sheet cushion for advancing clinical programs and absorbing operating volatility over the medium term.
Targeted Oncology PlatformA focused oncology strategy using antibody discovery and protein engineering can support differentiated therapies for genetically or molecularly defined cancers, creating potential for valuable programs if clinical development succeeds.
Pipeline Expansion FlexibilityCombining internal discovery with in-licensed assets broadens the development pipeline and gives Immunome multiple routes to add candidates, potentially improving portfolio depth and reducing dependence on one program.
Bears Say
No Current RevenueThe absence of trailing revenue indicates that Immunome has not established a recurring commercial or collaboration revenue base, leaving future funding capacity highly dependent on pipeline progress and new transactions.
Severe Cash BurnPersistent and worsening cash outflows require substantial financial resources to sustain research and clinical development, increasing the likelihood of future capital needs and potential dilution despite low debt.
Large Persistent LossesLarge recurring losses show that development spending currently far exceeds recognized income. Without successful clinical, licensing or commercial milestones, profitability and durable self-funded growth remain distant.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $8.66 and its highest was $30.06 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $3.13B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Nov 16, 2026 which is in 78 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Aug 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.136.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.6.
How many shares outstanding does Immunome have?
Immunome has 113,577,630 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went up 6.629%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.30 (23.55% Upside)
$36.30 (23.55% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 486.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $440.0 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
90.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunome
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Stock 12 Month Forecast
Average Price Target
$36.30
▲(23.55% Upside)
Technical Analysis
Ownership Overview
1.50% Insiders
36.40% Mutual Funds
45.05% Other Institutional Investors
3.54% Public Companies and
Individual Investors